NASDAQ:LABP

Landos Biopharma Competitors

$11.25
+0.64 (+6.03 %)
(As of 04/14/2021 03:56 PM ET)
Add
Compare
Today's Range
$10.51
Now: $11.25
$11.46
50-Day Range
$9.26
MA: $12.17
$16.26
52-Week Range
$8.82
Now: $11.25
$16.99
Volume1,589 shs
Average Volume292,816 shs
Market Capitalization$451.33 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Landos Biopharma (NASDAQ:LABP) Vs. BCAB, IMCR, CGEM, EWTX, KNTE, and SBTX

Should you be buying LABP stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Landos Biopharma, including BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), Cricut (EWTX), Kinnate Biopharma (KNTE), and Silverback Therapeutics (SBTX).

Landos Biopharma (NASDAQ:LABP) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Profitability

This table compares Landos Biopharma and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Landos BiopharmaN/AN/AN/A
BioAtlaN/AN/AN/A

Earnings & Valuation

This table compares Landos Biopharma and BioAtla's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Landos BiopharmaN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for Landos Biopharma and BioAtla, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Landos Biopharma01302.75
BioAtla00403.00

Landos Biopharma presently has a consensus price target of $25.50, suggesting a potential upside of 126.67%. BioAtla has a consensus price target of $58.00, suggesting a potential upside of 25.98%. Given Landos Biopharma's higher probable upside, research analysts clearly believe Landos Biopharma is more favorable than BioAtla.

Summary

BioAtla beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.

Landos Biopharma (NASDAQ:LABP) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares Landos Biopharma and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Landos BiopharmaN/AN/AN/A
ImmunocoreN/AN/AN/A

Valuation & Earnings

This table compares Landos Biopharma and Immunocore's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Landos BiopharmaN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Landos Biopharma and Immunocore, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Landos Biopharma01302.75
Immunocore01202.67

Landos Biopharma presently has a consensus price target of $25.50, suggesting a potential upside of 126.67%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 37.59%. Given Landos Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Landos Biopharma is more favorable than Immunocore.

Summary

Landos Biopharma beats Immunocore on 3 of the 3 factors compared between the two stocks.

Landos Biopharma (NASDAQ:LABP) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares Landos Biopharma and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Landos BiopharmaN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Valuation & Earnings

This table compares Landos Biopharma and Cullinan Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Landos BiopharmaN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Landos Biopharma and Cullinan Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Landos Biopharma01302.75
Cullinan Oncology01302.75

Landos Biopharma presently has a consensus price target of $25.50, suggesting a potential upside of 126.67%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 35.99%. Given Landos Biopharma's higher probable upside, analysts plainly believe Landos Biopharma is more favorable than Cullinan Oncology.

Summary

Landos Biopharma beats Cullinan Oncology on 1 of the 1 factors compared between the two stocks.

Landos Biopharma (NASDAQ:LABP) and Cricut (NASDAQ:EWTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Landos Biopharma and Cricut's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Landos BiopharmaN/AN/AN/AN/AN/A
CricutN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Landos Biopharma and Cricut, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Landos Biopharma01302.75
Cricut0000N/A

Landos Biopharma presently has a consensus price target of $25.50, suggesting a potential upside of 126.67%. Given Landos Biopharma's higher probable upside, analysts plainly believe Landos Biopharma is more favorable than Cricut.

Profitability

This table compares Landos Biopharma and Cricut's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Landos BiopharmaN/AN/AN/A
CricutN/AN/AN/A

Summary

Landos Biopharma beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Kinnate Biopharma and Landos Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kinnate BiopharmaN/AN/AN/AN/AN/A
Landos BiopharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Kinnate Biopharma and Landos Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kinnate Biopharma00403.00
Landos Biopharma01302.75

Kinnate Biopharma currently has a consensus price target of $52.00, indicating a potential upside of 70.49%. Landos Biopharma has a consensus price target of $25.50, indicating a potential upside of 126.67%. Given Landos Biopharma's higher possible upside, analysts clearly believe Landos Biopharma is more favorable than Kinnate Biopharma.

Profitability

This table compares Kinnate Biopharma and Landos Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kinnate BiopharmaN/AN/AN/A
Landos BiopharmaN/AN/AN/A

Summary

Kinnate Biopharma beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Silverback Therapeutics and Landos Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/AN/AN/AN/A
Landos BiopharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Silverback Therapeutics and Landos Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silverback Therapeutics00403.00
Landos Biopharma01302.75

Silverback Therapeutics currently has a consensus price target of $50.25, indicating a potential upside of 32.10%. Landos Biopharma has a consensus price target of $25.50, indicating a potential upside of 126.67%. Given Landos Biopharma's higher possible upside, analysts clearly believe Landos Biopharma is more favorable than Silverback Therapeutics.

Profitability

This table compares Silverback Therapeutics and Landos Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silverback TherapeuticsN/AN/AN/A
Landos BiopharmaN/AN/AN/A

Summary

Silverback Therapeutics beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.


Landos Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioAtla logo
BCAB
BioAtla
1.5$46.04+0.1%$1.55 billionN/A0.00News Coverage
Immunocore logo
IMCR
Immunocore
1.3$39.49+16.4%$1.42 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.48+9.0%$1.40 billionN/A0.00
EWTX
Cricut
0.3$28.38+1.8%$1.33 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$30.85+8.0%$1.23 billionN/A0.00Increase in Short Interest
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.5$38.04+10.4%$1.19 billionN/A0.00Analyst Report
News Coverage
Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.92+11.2%$1.18 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
Vor Biopharma logo
VOR
Vor Biopharma
1.9$33.68+13.5%$1.08 billionN/A0.00
FDMT
4D Molecular Therapeutics
1.1$37.69+5.2%$954.04 millionN/A0.00Increase in Short Interest
Gap Down
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.0$17.41+2.6%$946.10 millionN/A0.00Analyst Report
News Coverage
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.50+2.2%$918.27 millionN/A0.00Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.97+6.9%$908.70 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$24.05+3.8%$876.07 millionN/A0.00Analyst Report
Increase in Short Interest
PHAR
Pharming Group
0.0$12.93+2.5%$845.43 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Up
FNCH
Finch Therapeutics Group
2.0$16.43+3.5%$801.47 millionN/A0.00Analyst Report
News Coverage
Gap Up
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.87+8.0%$798.13 millionN/A0.00Analyst Report
SGTX
Sigilon Therapeutics
1.4$20.08+7.2%$587.03 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
1.4$13.75+1.7%$540.43 millionN/A0.00News Coverage
Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.51+2.3%$506.10 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
NexImmune logo
NEXI
NexImmune
2.0$24.08+13.0%$476.78 millionN/A0.00News Coverage
Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$21.61+17.6%$447.23 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.79+3.0%$438.63 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.20+6.0%$421.33 millionN/A0.00
PRTG
Portage Biotech
0.0$28.17+3.8%$353.43 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.85+3.9%$302.37 millionN/A-2.71
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.61+2.5%$299.20 millionN/A-2.98Gap Down
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.86+4.1%$259.23 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$10.87+8.0%$224.46 millionN/A0.00Increase in Short Interest
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$12.41+4.4%$200.64 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$23.13+4.3%$167.63 millionN/A0.00
VINC
Vincerx Pharma
1.0$18.98+0.3%$155.32 millionN/A0.00
GANX
Gain Therapeutics
1.7$14.18+6.9%$149.57 millionN/A0.00Analyst Report
Gap Up
LGVN
Longeveron
0.3$7.49+2.3%$136.94 millionN/A0.00News Coverage
Gap Up
EVAX
Evaxion Biotech A/S
1.7$7.31+10.9%$124.99 millionN/A0.00News Coverage
Gap Down
UPC
Universe Pharmaceuticals
0.0$3.88+5.4%$88.96 millionN/A0.00Gap Down
VRDN
Viridian Therapeutics
1.7$14.62+5.1%$60.07 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.21+4.2%$54.58 millionN/A0.00Gap Up
VIRI
Virios Therapeutics
1.3$5.95+1.7%$48.73 millionN/A0.00Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.29+2.1%$37.93 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$5.05+1.4%$34.87 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$4.60+2.8%$23.39 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$35.00+12.4%$18.25 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.84+4.9%$14.91 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.18+13.5%$2.79 millionN/A0.00News Coverage
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.61+4.7%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.77+1.4%$0.00N/A0.00News Coverage
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00Increase in Short Interest
News Coverage
RPHM
Reneo Pharmaceuticals
0.3$12.62+3.1%$0.00N/A0.00Insider Buying
News Coverage
SCPS
Scopus BioPharma
1.4$7.89+1.3%$0.00N/A0.00Increase in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.